Telix Pharmaceuticals Limited Share Price
Equities
TLX
AU000000TLX2
Biotechnology & Medical Research
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.930 AUD | +0.56% |
|
-8.41% | -20.27% |
| Capitalization | 3.01B 2.12B 1.8B 1.64B 1.57B 2.9B 192B 19.14B 7.58B 92.86B 7.95B 7.78B 328B | P/E ratio 2025 * |
-1,343x | P/E ratio 2026 * | 1,298x |
|---|---|---|---|---|---|
| Enterprise value | 3.36B 2.37B 2.01B 1.83B 1.75B 3.24B 215B 21.4B 8.47B 104B 8.88B 8.7B 367B | EV / Sales 2025 |
3.17x | EV / Sales 2026 * | 2.51x |
| Free-Float |
58.65% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Telix Pharmaceuticals Limited
| 1 day | +0.56% | ||
| 1 week | -8.41% | ||
| Current month | -15.36% | ||
| 1 month | -20.83% | ||
| 3 months | -36.49% | ||
| 6 months | -49.66% | ||
| Current year | -20.27% |
| 1 week | 8.26 |  | 9.59 |
| 1 month | 8.26 | | 11.99 |
| Current year | 8.26 | | 11.99 |
| 1 year | 8.26 | | 31.97 |
| 3 years | 5.82 | | 31.97 |
| 5 years | 3.47 | | 31.97 |
| 10 years | 0.46 | | 31.97 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 51 | 02/01/2017 | |
Darren Smith
DFI | Director of Finance/CFO | 60 | 30/07/2022 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 51 | 02/01/2017 | |
Mark Nelson
CHM | Chairman | 66 | 02/02/2026 |
Jann Skinner
BRD | Director/Board Member | 68 | 18/06/2018 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.56% | -8.41% | -67.22% | +45.44% | 2.12B | |
| -0.60% | +3.17% | -11.43% | -3.86% | 48.77B | |
| +1.18% | +1.59% | +55.53% | +54.72% | 39.27B | |
| -0.21% | +4.62% | +36.37% | +68.00% | 36.05B | |
| +4.03% | -6.24% | -11.57% | -22.15% | 27.89B | |
| -0.82% | +3.97% | +145.37% | +289.96% | 19.45B | |
| +1.05% | +19.57% | +32,220.16% | +4,381.60% | 15.61B | |
| +1.91% | -0.24% | +35.54% | -0.94% | 13.78B | |
| +1.53% | +1.18% | +57.43% | +94.45% | 13.71B | |
| +1.06% | -2.46% | +164.88% | +113.01% | 13.18B | |
| Average | +0.97% | +0.29% | +3,262.51% | +502.02% | 22.98B | |
| Weighted average by Cap. | +0.80% | +1.42% | +2,226.61% | +351.15% |
| 2025 | 2026 * | |
|---|---|---|
| Net sales | 1.23B 867M 735M 670M 642M 1.19B 78.7B 7.83B 3.1B 38B 3.25B 3.18B 134B | 1.37B 964M 817M 744M 713M 1.32B 87.46B 8.71B 3.45B 42.23B 3.61B 3.54B 149B |
| Net income | 680K 479K 406K 370K 354K 656K 43.46M 4.33M 1.71M 20.98M 1.8M 1.76M 74.1M | 31.1M 21.91M 18.58M 16.92M 16.22M 30M 1.99B 198M 78.34M 960M 82.15M 80.46M 3.39B |
| Net Debt | 354M 250M 212M 193M 185M 342M 22.66B 2.26B 893M 10.94B 936M 917M 38.64B | 427M 301M 255M 233M 223M 412M 27.33B 2.72B 1.08B 13.2B 1.13B 1.11B 46.6B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 18/02/26 | 8.930 $ | +0.56% | 343,318 |
| 18/02/26 | 8.880 $ | +0.45% | 2,225,222 |
| 17/02/26 | 8.840 $ | +2.43% | 3,867,207 |
| 16/02/26 | 8.630 $ | -1.48% | 2,345,498 |
| 13/02/26 | 8.760 $ | -3.52% | 3,334,991 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- TLX Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition